Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Core Insights - Spruce Biosciences reported a productive year in 2025, focusing on the development of TA-ERT for MPS IIIB, with a BLA submission expected in Q4 2026 [1][2] - The company appointed Dale Hooks as Chief Commercial Officer to enhance commercial capabilities ahead of the potential launch of TA-ERT [1][3] - Spruce secured up to $50 million in growth capital from Avenue Capital to support the advancement of TA-ERT [1][2] Corporate Updates - Positive Type B meetings with the FDA were held, confirming that existing clinical data could support an accelerated approval for TA-ERT [1][2] - Dale Hooks, with over 30 years of experience in biopharmaceutical marketing, was appointed as Chief Commercial Officer [1][3] - A loan facility of up to $50 million was established, with an initial tranche of $15 million fully funded in January 2026 [1][2] - Long-term data presented at the 22nd Annual WORLD Symposium indicated TA-ERT may be the first disease-modifying treatment for MPS IIIB [1][2] - Regulatory and clinical development expertise was added to the executive team with new appointments in February 2026 [1][2] - The Rare Pediatric Disease Priority Review Voucher program was reauthorized, providing incentives for developing therapies for rare pediatric diseases [1][2] Financial Results for 2025 - Cash and cash equivalents as of December 31, 2025, were $48.9 million, expected to fund operations into early 2027 [2] - Research and Development (R&D) expenses decreased to $19.5 million from $46.4 million in 2024, primarily due to the cessation of tildacerfont development [2] - General and Administrative (G&A) expenses increased to $17.0 million from $14.6 million in 2024, driven by higher professional service fees [2] - Total operating expenses for 2025 were $36.5 million, down from $61.1 million in 2024 [2] - The net loss for 2025 was $39.0 million, compared to a net loss of $53.0 million in 2024 [2]